Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 12/20 | 0.41 |
| ▸ | ITGA2B | P08514 | 12/20 | 0.41 |
| ▸ | ITGAV | P06756 | 11/20 | 0.38 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.38 |
| ▸ | ACE | P12821 | 1/20 | 0.37 |
| ▸ | ITGB6 | P18564 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3051444 | 0.91 | ITGB3 (0.39) | ITGB3ITGA2BITGAVITGB6 | |
| SCHEMBL3048532 | 0.81 | ITGB3 (0.44) | ITGB3ITGA2BITGAV | |
| SCHEMBL3045371 | 0.81 | ITGB3 (0.48) | ITGB3ITGA2BITGAV | |
| SCHEMBL3048690 | 0.80 | ITGB3 (0.38) | ITGB3ITGA2BITGAV | |
| SCHEMBL3043268 | 0.78 | ITGB1 (0.45) | ITGB3ITGA2BITGAV | |
| SCHEMBL18262461 | 0.73 | ACE (0.52) | ITGB3ITGA2BITGAVPTPN1ACE | |
| SCHEMBL18262463 | 0.73 | ACE (0.52) | ITGB3ITGA2BITGAVPTPN1ACE | |
| SCHEMBL7164260 | 0.72 | TSHR (0.42) | ITGB3ITGA2BITGAVPTPN1ACE | |
| SCHEMBL7163716 | 0.71 | ACE (0.41) | ITGB3ITGA2BITGAVPTPN1ACE | |
| SCHEMBL7163504 | 0.71 | ACE (0.41) | ITGB3ITGA2BITGAVPTPN1ACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7645736-B2 | injecting an alpha-v. beta 3 or alpha-v, beta 5 inhibitor into the vitreous body of the eye; angiogenesis inhibition; diabetic retinopathy, macular degeneration, myopia, ocular histoplasmosis; (2S)-2-benzyloxycarboxamido-3-(2-guanidinomethyl-1,4-benzodioxan-6-yl)propionic acid | MERCK PATENT GMBH (DE) | 2010-01-12 | — | — | US | claimed |
| US-20060287225-A1 | Integrin inhibitors for the treatment of eye diseases | SCRIPPS RESEARCH INSTITUTE, THE | 2006-12-21 | — | — | US | claimed |
| EP-1411926-B1 | INTEGRIN INHIBITORS FOR THE TREATMENT OF EYE DISEASES | MERCK PATENT GMBH (DE) | 2005-06-01 | — | — | EP | claimed |
| US-20040198644-A1 | Integrin inhibitors for the treatment of eye diseases | MERCK PATENT GESELLSCHAFT (DE) | 2004-10-07 | — | — | US | claimed |
| US-7645736-B2 | injecting an alpha-v. beta 3 or alpha-v, beta 5 inhibitor into the vitreous body of the eye; angiogenesis inhibition; diabetic retinopathy, macular degeneration, myopia, ocular histoplasmosis; (2S)-2-benzyloxycarboxamido-3-(2-guanidinomethyl-1,4-benzodioxan-6-yl)propionic acid | MERCK PATENT GMBH (DE) | 2010-01-12 | — | — | US | disclosed |
| US-20060287225-A1 | Integrin inhibitors for the treatment of eye diseases | SCRIPPS RESEARCH INSTITUTE, THE | 2006-12-21 | — | — | US | disclosed |
| EP-1411926-B1 | INTEGRIN INHIBITORS FOR THE TREATMENT OF EYE DISEASES | MERCK PATENT GMBH (DE) | 2005-06-01 | — | — | EP | disclosed |
| US-20040198644-A1 | Integrin inhibitors for the treatment of eye diseases | MERCK PATENT GESELLSCHAFT (DE) | 2004-10-07 | — | — | US | disclosed |
| EP-1411926-A1 | INTEGRIN INHIBITORS FOR THE TREATMENT OF EYE DISEASES | MERCK PATENT GmbH (DE) | 2004-04-28 | — | — | EP | disclosed |
| WO-2003013511-A1 | INTEGRIN INHIBITORS FOR THE TREATMENT OF EYE DISEASES | MERCK PATENT GMBH (DE) | 2003-02-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040198644-A1 | Integrin inhibitors for the treatment of eye diseases | ITGA5, ITGB5, ITGAV | ITGB3 5/4885ITGA2B 7/4885ITGAV 3/4885 |
| US-20060287225-A1 | Integrin inhibitors for the treatment of eye diseases | ITGA5, ITGAV, ITGB5 | ITGB3 4/4885ITGA2B 7/4885ITGAV 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.